Below copied from IHUB AVXL board, Fletch falc
Post# of 1460
(Total Views: 796)
Posted On: 04/23/2018 4:10:23 PM
Below copied from IHUB AVXL board,
Fletch
falconer66a Monday, 04/23/18 08:26:18 AM
Re: XenaLives post# 148508 0
Post # of 148554
No Obvious Corrective Mechanism
After reading and pondering the abstract, I didn’t detect any obvious mechanism by which sigma-1 receptor agonists might correct any of the aberrant chemistries described.
Nonetheless, sigma-1 receptor agonists might be helpful. By restoring homeostatic processes, suppression of epigenetic or hypoxic processes that induce the involved pathologies might occur.
Of course, this would need to be tested, either on murines (rats, mice) with the various abnormal chemistries — or on humans.
What, test on humans? Can’t do that! No one knows just how dangerous Anavex sigma-1 receptor agonists might be in humans.
Except.... For a number of Australians who have been popping Anavex 2-73 for up to three years now, with no reported adverse events, no hazardous or debilitating side events. And, for thousands of lab murines, for which not a single well-dosed adverse outcome has been recorded. Simply, Anavex sigma-1 receptor agonists are utterly safe.
I, too, have a central nervous system disease, hereditary spastic paraplegia, for which I, would jump at the chance take Anavex 2-73, without any preliminary murine tests. In my case, a French researcher administered the drug to a bunch of transgenic lab rats that had my genes, with all of the consequent nervous system debilities, notably leg spasticity. After drinking water for some time that had Anavex 2-73 dissolved in it, the rats began using their rear legs normally
Unfortunately, I mis-copied that article on my computer, and can no longer find it. If anyone knows of this otherwise very obscure research paper, please post it.
In short, the broad-spectrum applications of Anavex sigma-1 receptor agonists, I’m certain, will not be limited to Rett syndrome, Parkinson’s, and Alzheimer’s diseases. The ability to restore normalized homeostatic processes will treat and correct any number of other diseases, yet to be revealed. Anavex researchers almost surely know of them already, from initial murine studies. Too early to be talking publicly about them. But quiet conversations with FDA officials, drug manufacturers (not marketers), university researchers, and other parties are surely happening. The expertise of the Anavex advisors guarantee such knowledge and discussions.
PS Been adding to my IPIX holdings.........added some more today at .44 :>
Fletch
falconer66a Monday, 04/23/18 08:26:18 AM
Re: XenaLives post# 148508 0
Post # of 148554
No Obvious Corrective Mechanism
After reading and pondering the abstract, I didn’t detect any obvious mechanism by which sigma-1 receptor agonists might correct any of the aberrant chemistries described.
Nonetheless, sigma-1 receptor agonists might be helpful. By restoring homeostatic processes, suppression of epigenetic or hypoxic processes that induce the involved pathologies might occur.
Of course, this would need to be tested, either on murines (rats, mice) with the various abnormal chemistries — or on humans.
What, test on humans? Can’t do that! No one knows just how dangerous Anavex sigma-1 receptor agonists might be in humans.
Except.... For a number of Australians who have been popping Anavex 2-73 for up to three years now, with no reported adverse events, no hazardous or debilitating side events. And, for thousands of lab murines, for which not a single well-dosed adverse outcome has been recorded. Simply, Anavex sigma-1 receptor agonists are utterly safe.
I, too, have a central nervous system disease, hereditary spastic paraplegia, for which I, would jump at the chance take Anavex 2-73, without any preliminary murine tests. In my case, a French researcher administered the drug to a bunch of transgenic lab rats that had my genes, with all of the consequent nervous system debilities, notably leg spasticity. After drinking water for some time that had Anavex 2-73 dissolved in it, the rats began using their rear legs normally
Unfortunately, I mis-copied that article on my computer, and can no longer find it. If anyone knows of this otherwise very obscure research paper, please post it.
In short, the broad-spectrum applications of Anavex sigma-1 receptor agonists, I’m certain, will not be limited to Rett syndrome, Parkinson’s, and Alzheimer’s diseases. The ability to restore normalized homeostatic processes will treat and correct any number of other diseases, yet to be revealed. Anavex researchers almost surely know of them already, from initial murine studies. Too early to be talking publicly about them. But quiet conversations with FDA officials, drug manufacturers (not marketers), university researchers, and other parties are surely happening. The expertise of the Anavex advisors guarantee such knowledge and discussions.
PS Been adding to my IPIX holdings.........added some more today at .44 :>
(1)
(0)